SCHEMBL893373

SCHEMBL893373

C=CP(C)(=O)C=C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL778351 0.78
SCHEMBL196701 0.72
SCHEMBL8742418 0.72
Hydrochloric Acid SCHEMBL11342308 0.69
SCHEMBL11295695 0.67
SCHEMBL779693 0.67
SCHEMBL777478 0.65
SCHEMBL26220024 0.65
Methyl Phosphonate SCHEMBL29180890 0.64 CA2 (0.61)
Methyl Alcohol SCHEMBL28243374 0.64

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024182788-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. (US) 2024-09-06 WO disclosed
EP-3398947-B1 NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUND, AS WELL AS PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND APPLICATION THEREOF SHANGHAI PHARMACEUTICALS HOLDING CO LTD (CN) 2024-08-28 EP disclosed
EP-3565815-B1 COMPOUNDS AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOCHON PHARMACEUTICALS LTD (CN) 2024-03-13 EP disclosed
CN-116355484-A Curable composition, cured film, organic electroluminescent element, and method for producing organic electroluminescent element JSR株式会社 2023-06-30 CN disclosed
CN-106928219-B Nitrogen-containing fused heterocyclic compound, preparation method, intermediate, composition and application 上海医药集团股份有限公司 2021-08-20 CN disclosed
US-11053239-B2 Compounds as BLC-2-selective apoptosis-inducing agents FOCHON PHARMACEUTICALS, LTD. (CN) 2021-07-06 US disclosed
US-10988476-B2 Substituted pyrimidines as cyclin-dependent kinase inhibitors SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2021-04-27 US disclosed
WO-2020245434-A1 BRIDGED PHOSPHORUS-BASED FLAME RETARDANTS EMPA EIDGENÖSSISCHE MATERIALPRÜFUNGS- UND FORSCHUNGSANSTALT (CH) 2020-12-10 WO disclosed
US-20200317705-A1 PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS ARIAD PHARMACEUTICALS, INC. 2020-10-08 US disclosed
US-20200239470-A1 Substituted Pyrimidine Compound for Treating Cancer SHANGHAI PHARMACEUTICALS HOLDING CO LTD (CN) 2020-07-30 US disclosed
US-7625880-B2 Inhibitors of tyrosine kinases and uses thereof PHARMACYCLICS, INC. (US) 2009-12-01 US disclosed
WO-2009143389-A1 PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS ARIAD PHARMACEUTICALS, INC. (US) 2009-11-26 WO disclosed
US-20090270351-A1 PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS MERCK SHARP & DOHME CORP. 2009-10-29 US disclosed
CN-101421269-A Inhibitors of tyrosine kinases and uses thereof PHARMACYCLICS INC (US) 2009-04-29 CN disclosed
EP-1981888-A2 INHIBITORS OF TYROSINE KINASES AND USES THEREOF Pharmacyclics, Inc. (US) 2008-10-22 EP disclosed
US-20080039426-A1 INHIBITORS OF TYROSINE KINASES AND USES THEREOF PHARMACYCLICS, INC. (US) 2008-02-14 US disclosed
US-20080039426-A1 INHIBITORS OF TYROSINE KINASES AND USES THEREOF PHARMACYCLICS, INC. (US) 2008-02-14 US disclosed
US-20080039426-A1 INHIBITORS OF TYROSINE KINASES AND USES THEREOF PHARMACYCLICS, INC. (US) 2008-02-14 US disclosed
WO-2008010985-A2 PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS MERCK & CO., INC. (US) 2008-01-24 WO disclosed
WO-2007087068-A2 INHIBITORS OF TYROSINE KINASES AND USES THEREOF PHARMACYCLICS, INC. (US) 2007-08-02 WO disclosed